<DOC>
	<DOC>NCT00972322</DOC>
	<brief_summary>This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes. The primary hypothesis of the study is that after 4 weeks of treatment, MK-8245 produces a greater reduction in 24 hour weighted mean glucose (WMG) from baseline than placebo.</brief_summary>
	<brief_title>Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Subject has a diagnosis of type 2 diabetes and is being treated with diet and exercise alone, a single oral antihyperglycemic agent or a combination of two oral antihyperglycemic agents Subject is willing to follow a weightmaintaining diet and exercise program during the study Subject is a nonsmoker or is willing to limit smoking to 10 cigarettes per day while in the clinical research unit Subject has a history of stroke, chronic seizures, or major neurological disorder Subject has a history of cancer, except certain skin and cervical cancers or cancer that was successfully treated 10 or more years prior to screening Subject has a history of type 1 diabetes Subject has used contact lenses within the last 6 months Subject has used any lipidlowering therapy in the last 3 months, except statins, Zetia, or Vytorin Subject has more than 3 alcoholic beverages per day Subject has more than 6 servings of caffeine a day Subject has participated in a previous MK8245 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>